APC-APN-201
26 evidence topics · 2 sources
Objective
Pharmacokinetics, efficacy, tolerability, and safety with concomitant GLP-1 receptor agonists
Location and study date
Registered study dates and sites
| Field | Quoted record |
|---|---|
| Study start (actual) | “2024-05-20” |
| Primary completion (actual) | “2024-12-26” |
| Number of locations | “This study has 4 locations” |
| Alabama site | “Anniston, Alabama, United States, 36207 Pinnacle Research Group, LLC” |
| Florida site | “Jacksonville, Florida, United States, 32256 Clinical Neuroscience Solutions, Inc” |
| North Carolina site | “Monroe, North Carolina, United States, 28112 Monroe Biomedical Research” |
| Tennessee site | “Memphis, Tennessee, United States, 38119 Clinical Neuroscience Solutions, Inc” |
Study design
Open-label, parallel-arm, 6-week phase 2 design
Arms defined by concomitant GLP-1 receptor agonist use
Registered design details
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Inclusion: age, body mass index, and REI4 range on home sleep apnea testing
Inclusion: stable GLP-1 receptor agonist dose or eligibility for one
Exclusion: insomnia, urinary, glaucoma, psychiatric, and bariatric surgery criteria
Treatment
Registered arms and administration
Permitted GLP-1 receptor agonists
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Primary outcome: spontaneously reported adverse events at 6 weeks
Efficacy outcome: REI4 responder at week 5 by home sleep apnea test
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “Enrollment (Actual) 40” |
Description of analysis sets
Pharmacokinetic analysis: noncompartmental analysis and mixed-effects model
Results
Participant disposition
Participants enrolled and treated by arm
Baseline characteristics
No evidence found.
Efficacy results
REI4 responder rate at week 5 with and without a GLP-1 receptor agonist
Pharmacokinetics: geometric mean ratios with versus without a GLP-1 receptor agonist
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events, serious events, and deaths
Study limitations
Summary
- Design: open-label, 6-week phase 2 study with no placebo arm; the arms differ only in concomitant GLP-1 receptor agonist use, while the registry lists the allocation as randomized.
- Size: 40 participants at 4 U.S. sites, with 22 receiving AD109 alone and 18 receiving AD109 with a GLP-1 receptor agonist, against about 20 planned per arm.
- Population: ages 18 to 75, BMI 27 to 43 (men) or 45 (women) kg/m2, and REI4 above 5 and below 45 on home sleep apnea testing. Exclusions included bothersome insomnia or bladder outlet obstruction, narrow angle glaucoma, and prior gastric weight loss surgery. Prior device users enrolled after 2 weeks without use.
- Endpoints: the primary outcome was spontaneously reported adverse events. Efficacy was the proportion with at least 50% REI4 reduction on home sleep apnea testing at week 5, reported as 33.3% and 29.4%.
- Reporting: results are available only from a congress abstract, without baseline characteristics or PROs.
- Sponsor: the abstract states the study was supported by Apnimed.